Companies in #Metabolic Disorders

Eton Pharmaceuticals is a commercial-stage specialty pharmaceutical company developing, acquiring, and commercializing high-potential therapies for the treatment of rare diseases. The company's commercial portfolio includes Alkindi Sprinkle (hydrocortisone pediatric granules), Carglumic Acid (N-carbamylglutamate for hyperammonemia), Rezipres (ephedrine injection), and Betaine Anhydrous. Eton also operates a royalty-monetization business that has provided non-dilutive capital to fund late-stage clinical assets in-licensed from larger developers. In July 2026, Canaccord Genuity raised its price target on Eton to $60, citing accelerating rare-disease commercial momentum.

Commercial-stage rare disease biopharmaceutical company focused on melanocortin-4 receptor (MC4R) pathway therapeutics; lead product IMCIVREE (setmelanotide) treats hyperphagia and severe obesity caused by POMC, PCSK1, LEPR and Bardet-Biedl syndrome deficiencies.

Clinical-stage cardiometabolic biotech developing next-generation oral and injectable peptide therapies for obesity and related metabolic conditions, led by an oral formulation of ecnoglutide and a portfolio of amylin-based candidates.